Articles about immunotherapy – Page 3 of 3

Chinese researchers become first to test CRISPR gene editing in humans, using immune cells to attack cancer

Researchers at Sichuan University in Chengdu, China, have injected the first CRISPR-edited cells into a patient. The procedure is part of… Read More

Fred Hutch unveils first-of-its-kind Immunotherapy Clinic, named after Bezos family

To many, immunotherapies — treatments that use a patient’s immune system to fight cancer— sound like something from an episode of… Read More

Study of Juno Therapeutics cancer treatment shows high rates of remission, possible promise for other drugs

A study published today on a Juno Therapeutics immunotherapy treatment for blood cancers shows that the drug and others like it could… Read More

Seattle startup raises $2M to expand technologies for immunotherapy

Take a quick browse through Seattle’s biotech scene, and you’ll notice a pattern. Immunotherapy — using the body’s immune system to fight… Read More

Juno posts loss as it amps up R&D spending for cancer trials

It’s been a busy quarter for Juno Therapeutics with several different immunotherapy trials underway and a big hiring push as it… Read More

Seattle just got another publicly traded biotech company

Seattle-based Aptevo Therapeutics completed a spinoff from Emergent BioSolutions Monday, making a debut in the public markets as a standalone company.… Read More

Juno Therapeutics resumes cancer clinical trial after removing suspect drug

Seattle-based Juno Therapeutics says it’s resuming a clinical trial of its immunotherapy treatment, a week after the Food and Drug… Read More

Alpine Immune Sciences raises $48 million for cancer and autoimmune treatment

Seattle’s Alpine Immune Sciences says it has closed a $48 million Series A financing round, to fund the development of… Read More

Fast-growing Adaptive Biotechnologies appoints president of new therapeutics division

Adaptive Biotechnologies, the heavily-funded Seattle bioinformatics company, today announced that Diego Miralles will become the president of a new division of… Read More